Elliott Management’s CorMedix CRMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-833,374
Closed -$6.07M 4
2019
Q4
$6.07M Hold
833,374
0.05% 51
2019
Q3
$5.32M Buy
833,374
+1
+0% +$8 0.04% 51
2019
Q2
$7.47M Hold
833,373
0.05% 55
2019
Q1
$7.88M Sell
833,373
-1
-0% -$9 0.05% 63
2018
Q4
$5.38M Hold
833,374
0.04% 70
2018
Q3
$4.04M Hold
833,374
0.02% 68
2018
Q2
$990K Hold
833,374
﹤0.01% 80
2018
Q1
$755K Hold
833,374
﹤0.01% 69
2017
Q4
$2.09M Hold
833,374
0.01% 59
2017
Q3
$2.17M Hold
833,374
0.01% 77
2017
Q2
$1.78M Buy
833,374
+533,334
+178% +$1.82M 0.01% 80
2017
Q1
$2.44M Hold
300,040
0.02% 66
2016
Q4
$2.29M Hold
300,040
0.02% 73
2016
Q3
$3.78M Hold
300,040
0.03% 70
2016
Q2
$2.98M Hold
300,040
0.03% 78
2016
Q1
$3.98M Hold
300,040
0.04% 59
2015
Q4
$3.04M Hold
300,040
0.04% 69
2015
Q3
$2.98M Hold
300,040
0.06% 58
2015
Q2
$5.82M Hold
300,040
0.08% 50
2015
Q1
$14.8M Buy
300,040
+143,752
+92% +$3.41M 0.18% 37
2014
Q4
$1.49M Hold
156,288
0.02% 78
2014
Q3
$1.47M Hold
156,288
0.02% 70
2014
Q2
$1.41M Hold
156,288
0.02% 65
2014
Q1
$1.96M Hold
156,288
0.04% 47
2013
Q4
$969K Hold
156,288
0.02% 39
2013
Q3
$721K Hold
156,288
0.01% 44
2013
Q2
$742K Buy
+156,288
New +$564K 0.01% 43

Other funds holding CRMD

Elliott Management's CRMD Position: Q1 2020 in Review

Elliott Management sold out of CorMedix (CRMD) in Q1 2020, closing a stake of 833,374 shares — an estimated $6.07M sold.

Elliott Management first reported a position in CRMD in Q2 2013 and held it in 27 quarters. The position peaked at $14.8M in Q1 2015. 59 funds tracked by Wall St. Rank hold CRMD as of Q1 2020.

  • Elliott Management reported no remaining CorMedix position as of Q1 2020 after selling out during the quarter.
  • Elliott Management sold 833,374 CorMedix shares in Q1 2020, an estimated $6.07M.
  • Elliott Management first reported a position in CorMedix in Q2 2013 and held it in 27 quarters.
  • Elliott Management's CorMedix position peaked at $14.8M in Q1 2015.
  • 59 funds tracked by Wall St. Rank held CorMedix as of Q1 2020.

Based on Elliott Management's 13F filing for Q1 2020.